Klea Holding
PAR:ALKLH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (20.8), the stock would be worth €0.22 (27% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.4 | €0.18 |
0%
|
| 3-Year Average | 20.8 | €0.22 |
+27%
|
| 5-Year Average | 20.8 | €0.22 |
+27%
|
| Industry Average | 7.2 | €0.08 |
-56%
|
| Country Average | 7.3 | €0.08 |
-56%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€67.2m
|
/ |
Jul 2025
€3.2m
|
= |
|
|
€67.2m
|
/ |
Dec 2025
€8.4m
|
= |
|
|
€67.2m
|
/ |
Dec 2026
€11m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
Klea Holding
PAR:ALKLH
|
53.8m EUR | 16.4 | 21.7 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161B USD | 14 | 25.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
160.3B USD | 42.5 | 56.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.2B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.2B USD | 12.7 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.3B USD | 18.2 | 30.5 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 11.3 | 20.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.4B USD | 30.3 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
44.6B USD | 10 | 25.4 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
32.9B USD | 11.4 | 15.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 5.3 |
| Median | 7.3 |
| 70th Percentile | 11.7 |
| Max | 1 862.3 |
Other Multiples
Klea Holding
Glance View
Visiomed Group SA engages in the development and distribution of healthcare products and services. The company is headquartered in Paris, Ile-De-France and currently employs 94 full-time employees. The company went IPO on 2011-07-05. The firm focus on acquiring, developing, and digitizing companies in various sectors to maximize their growth and value. The company draws on its experience in developing Smart Salem, the network of digitalized medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the United Arab Emirates. The firm Smart Health joint venture developed in Saudi Arabia, to extend this entrepreneurial approach to the four corners of the globe. The company invests in companies from various sectors in the development phase, both in France and internationally.
